Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody─mediated rejection in kidney transplant ...
Biogen Inc., is a leading biotechnology company, announced the initiation of dosing in the global clinical study, TRANSCEND. The phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney …